{"webUser":null,"request_id":"ec94905e7a21474fb75ba61aa6851d0e"}
{"flashNotices":[],"request_id":"ec94905e7a21474fb75ba61aa6851d0e"}

Pharma Pulse / Pharma Pulse: Ipsen’s Global Tazemetostat Withdrawal and FDA Approval of Deucravacitinib for Psoriatic Arthritis

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.